QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
NASDAQ:IMMU

Immunomedics - IMMU Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$87.86
$87.86
50-Day Range
$85.08
$87.86
52-Week Range
$8.80
$87.93
Volume
N/A
Average Volume
4.01 million shs
Market Capitalization
$20.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMMU stock logo

About Immunomedics (NASDAQ:IMMU) Stock

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Receive IMMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

IMMU Stock News Headlines

"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Peak Gilead
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
See More Headlines

Receive IMMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

IMMU Company Calendar

Last Earnings
8/05/2020
Today
1/30/2023

Industry, Sector and Symbol

Industry
Diagnostic Substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMMU
CUSIP
45290710
Fax
N/A
Employees
366
Year Founded
N/A

Profitability

Net Income
$-357,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$290,000.00
Price / Sales
70,028.66
Book Value
$1.38 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.31 billion
Optionable
Optionable
Beta
2.90

Key Executives

  • Dr. Behzad Aghazadeh Ph.D. (Age 49)
    Exec. Chairman
    Comp: $147.53k
  • Mr. Usama Malik (Age 45)
    CFO & Chief Bus. Officer
    Comp: $533.39k
  • Mr. Brendan P. Delaney (Age 45)
    Chief Commercial Officer
    Comp: $527.63k
  • Mr. Bryan Ball (Age 50)
    Chief Quality Officer
    Comp: $646.48k
  • Mr. William Fricker (Age 55)
    Principal Accounting Officer, Exec. Director & Corp. Controller
  • Ms. Phyllis Parker
    Director of Admin.
  • Dr. Chau Cheng
    Sr. Director of Investor Relations
  • Mr. Jared Freedberg (Age 52)
    Gen. Counsel & Corp. Sec.
  • Mr. Kurt J. W. Andrews (Age 51)
    Chief HR Officer
  • Dr. Loretta M. Itri (Age 70)
    Chief Medical Officer













IMMU Stock - Frequently Asked Questions

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to analysts' expectations of $24.81 million.

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC).

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $87.86.

How much money does Immunomedics make?

Immunomedics (NASDAQ:IMMU) has a market capitalization of $20.31 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Immunomedics have?

The company employs 366 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The official website for the company is www.immunomedics.com. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at ccheng@immunomedics.com.

This page (NASDAQ:IMMU) was last updated on 1/30/2023 by MarketBeat.com Staff